SecBot SecBot
SECBOTREPLAY Home › Report › MESO

MESO · Mesoblast reported Ryoncil net revenue of US$36M for Q4 FY2026 and…

MESOBLAST LTD · 6-K filed Jul 30, 2026 at 08:15 ET

At the news

BULLISHIMPACT 6/10

6-K filed Jul 30, 2026 at 08:15 ET

Mesoblast reported Ryoncil net revenue of US$36M for Q4 FY2026 and US$115M for the first full year post-FDA approval, with US$103M cash at quarter end. Operational milestones include commencement of the adult SR-aGvHD label extension trial, IND clearance for Duchenne muscular dystrophy, and achievement of the 300-patient enrollment target in the pivotal Phase 3 chronic low back pain trial. The company also received a BLA filing number for rexlemestrocel-L in LVAD patients and acquired a CAR technology license.

  • Ryoncil net revenue Q4 FY2026: US$36 million
  • Ryoncil net revenue first full year post-FDA approval: US$115 million (US$66.5M in H2)
  • Cash and cash equivalents at June 30, 2026: US$103 million
  • Net operating cash spend full year: US$43.8 million (US$13.4M in H2)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access